Saccharomyces boulardii
Probiotic yeast with meta-analysis support for preventing antibiotic-associated diarrhoea; the evidence for C. difficile is weaker.
- Evidence
- Moderate evidenceGRADE certainty: Moderate
- Typical dose
- Adult: 250–500 mg twice daily during antibiotic course and 1–2 weeks after
- Time to effect
- Effect on AAD prevention requires concurrent dosing with antibiotics
- Safety
- Has documented cautions
Evidence ratings summarise published research on Saccharomyces boulardii in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.
Ask about Saccharomyces boulardii
Interactions
Taking any medication?
Check Saccharomyces boulardii against it.
Why
Saccharomyces boulardii is a non-pathogenic probiotic yeast, pharmacologically distinct from bacterial probiotics. A meta-analysis of 21 RCTs found S. boulardii lowered antibiotic-associated diarrhoea risk in adults and children, although one trial in elderly inpatients found no benefit. For C. difficile the evidence is thinner: a Cochrane review found insufficient evidence for treatment, and NICE advises against probiotics to avoid C. difficile infection in people taking antibiotics.
How it works
Resists antibiotic killing (a yeast, most antibiotics target bacteria), binds and neutralises C. difficile toxins A and B via a 54-kDa protease, restores brush-border enzyme activity, and modulates intestinal IgA. Cleared from the gut within 3–5 days of stopping intake, does not colonise.
Expected onset · Effect on AAD prevention requires concurrent dosing with antibiotics
How to take
Dosage
Adult: 250–500 mg twice daily during antibiotic course and 1–2 weeks after. Acute diarrhoea: 250 mg twice daily. Paediatric: per product label, weight-banded.
Timing
Separated from antifungals by at least 2 hours; otherwise with or without food
On the label
Specifically 'Saccharomyces boulardii' (often CNCM I-745 strain). Stable at room temperature unlike many bacterial probiotics.
Studied in
Adults and children starting antibiotic courses.
Safety
Evidence
Szajewska & Kołodziej 2015 Aliment Pharmacol Ther meta-analysis (21 RCTs, n=4780): S. boulardii lowered antibiotic-associated diarrhoea from 18.7% to 8.5% in children and adults on antibiotics. Pozzoni 2012 Am J Gastroenterol RCT (n=275) found no benefit in elderly inpatients. For C. difficile the evidence is thinner, and NICE guideline NG199 (2021) advises against probiotics to avoid C. difficile infection in people taking antibiotics.
GRADE certainty: Moderate — rated by Healicus using the GRADE method
- Goldenberg et al., Cochrane Database Syst Rev 2017, probiotics for the prevention of pediatric antibiotic-associated diarrhea
- Szajewska & Kołodziej, Aliment Pharmacol Ther 2015, systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea
- Szajewska H, Kołodziej M, Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea, Aliment Pharmacol Ther 2015
- Guo Q et al., Probiotics for the prevention of pediatric antibiotic-associated diarrhea, Cochrane Database Syst Rev 2019
- McFarland LV, Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease, Am J Gastroenterol 2006
- McFarland LV et al., A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease, JAMA 1994
- Pillai A, Nelson R, Probiotics for treatment of Clostridium difficile-associated colitis in adults, Cochrane Database Syst Rev 2008
- Pozzoni P et al., Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial, Am J Gastroenterol 2012
- Kotowska M et al., Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial, Aliment Pharmacol Ther 2005
- McFarland LV et al., Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo, Am J Gastroenterol 1995
- Szajewska H, Mrukowicz J, Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea, Aliment Pharmacol Ther 2005
- D'Souza AL et al., Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis, BMJ 2002
- NICE guideline (2021): Clostridioides difficile infection: antimicrobial prescribing (NG199)
Questions people ask
Does Saccharomyces boulardii work?
Szajewska & Kołodziej 2015 Aliment Pharmacol Ther meta-analysis (21 RCTs, n=4780): S. boulardii lowered antibiotic-associated diarrhoea from 18.7% to 8.5% in children and adults on antibiotics. Pozzoni 2012 Am J Gastroenterol RCT (n=275) found no benefit in elderly inpatients. For C. difficile the evidence is thinner, and NICE guideline NG199 (2021) advises against probiotics to avoid C. difficile infection in people taking antibiotics. Certainty of the evidence: Moderate, rated by Healicus using the GRADE method.
How is Saccharomyces boulardii taken?
Adult: 250–500 mg twice daily during antibiotic course and 1–2 weeks after. Acute diarrhoea: 250 mg twice daily. Paediatric: per product label, weight-banded. Timing: Separated from antifungals by at least 2 hours; otherwise with or without food. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.
Are there interactions or cautions?
Avoid in critically ill, immunocompromised, central-line-bearing, or severely ill patients, rare fungaemia reports in this group. Not with antifungal medication (fluconazole, etc.). Pregnancy data limited, with no specific concern documented; coordinate with the prescribing clinician. Documented drug and supplement interactions can be looked up in the free interaction reference.
What is the evidence based on?
Sources: Goldenberg et al., Cochrane Database Syst Rev 2017, probiotics for the prevention of pediatric antibiotic-associated diarrhea; Szajewska & Kołodziej, Aliment Pharmacol Ther 2015, systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea; Szajewska H, Kołodziej M, Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea, Aliment Pharmacol Ther 2015; Guo Q et al., Probiotics for the prevention of pediatric antibiotic-associated diarrhea, Cochrane Database Syst Rev 2019; McFarland LV, Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease, Am J Gastroenterol 2006; McFarland LV et al., A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease, JAMA 1994; Pillai A, Nelson R, Probiotics for treatment of Clostridium difficile-associated colitis in adults, Cochrane Database Syst Rev 2008; Pozzoni P et al., Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial, Am J Gastroenterol 2012; Kotowska M et al., Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial, Aliment Pharmacol Ther 2005; McFarland LV et al., Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo, Am J Gastroenterol 1995; Szajewska H, Mrukowicz J, Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea, Aliment Pharmacol Ther 2005; D'Souza AL et al., Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis, BMJ 2002; NICE guideline (2021): Clostridioides difficile infection: antimicrobial prescribing (NG199).
One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.